Good morning. Patrick speaking. And thank you very much for joining us on our quarterly call today.
We'll just jump right into it and talk a little bit about our highlights for the quarter.
First and foremost, we delivered strong earnings growth in the quarter.
We're very pleased about how that developed. And we'll talk a little bit more about where it came from and how it came to be.
Um, and as you might recall from the last time we met, we signaled that our organic revenue growth was going to be impacted by the adjustment in the annual order program. Therefore, our organic growth is a bit lower than you might have expected and have seen us achieve in the past. The remaining operating units that we have, the three others, all delivered double-digit organic growth in the quarter. And we also passed a very significant milestone a few weeks ago when we started to trade on the Large Cap market on the Nasdaq Main Market here in Stockholm.
It's a very important milestone for us as a publicly traded company.
And in general terms and overall, we are very well positioned. We're in an attractive market, and there are some fundamental underlying growth factors there that we really like, and we continue to view positively.
And we're also an agile business with an opportunity to steer and change our business, as the world around us is uncertain and changing. With that, let's go and dive a little bit deeper into the numbers.
For the quarter, we delivered an 18% revenue growth, reaching €107.5 million. Organic growth ended up being 4%, negatively impacted by the adjustment in the annual order program, which is limited to our MedTech Orthopaedics business in the US. The other segments delivered double-digit growth. Our adjusted EBITDA for the quarter also grew 18% to 28.3 million. Our margins were stable at 26.3. Exactly the same as we had last year.
And remember, we consolidated a new MedTech segment here in dental with our iM3 acquisition. At the time we acquired it, it had a lower margin profile than the rest of EMEA.
Now turning to our Specialty Pharma business, we experienced another quarter with strong performance, achieving 10% organic growth. Um, and we had growth across all our therapeutic areas. We had significant contributions from our specialty pharmaceuticals and our dermatology part of the business. Uh, we continue to innovate in this part of our business, and we see that the new launches contribute to growth. We had 23 new products that we launched this quarter, and the EBITA continued to grow nicely at 19%. Here, our margin improved from 27.8% to 28.8%, and that was driven predominantly by operational leverage and a positive mix. Returning to MedTech for a moment here, as expected and as we communicated in February, we saw an organic decline for our MedTech business, and it was primarily driven by the annual order program in our Orthopaedics part of the business in the US. Additionally, as we have noted since last summer, we've observed softness in the elective surgery market in the US. So that would be for our business and our hip business there. The other regions that we have, EMEA and APAC, continue to deliver high single-digit growth.
Um, and that's up from when we reported in Q4. And we continue to invest in education, especially in the US, to access the untapped opportunity, the untreated animals, and the untrained clinicians so that they can help us expand the addressable market.
In the first quarter here, we educated over 1,500 professionals in Orthopaedics.
That's about the same as we did in Q4. As you might recall, it was about 1600 back then, and the target for us in 2025 is to return this business to growth, which we're confident that we will be able to do.
When we look at it, our margin shows a clear sequential improvement, both year over year.
Um, and uh, the consolidation from Q4, we faced that AOP, which has an impact on our margins, and obviously the incorporation of iM3. Uh, at the end of the quarter as well, actually, right after we finished the quarter, we completed our first bolt-on acquisition with Dental Focus that we've welcomed to our family. That's a New Jersey-based company in the northeast part of America with revenues around $3 million.
It's a great strategic fit for us.
It complements the iM3 portfolio, and it also adds access to a new customer base, predominantly in the northeast of America.
So we're very excited to have that team join us.
We go to our veterinary services business, another double-digit revenue growth quarter, with phenomenal growth in EBITDA during this quarter. And as we mentioned, we have started to make some investments to grow our business organically. And one of these initiatives was launched in the first quarter, where we introduced DVM Grow, which is a new services platform targeting an untapped market segment in the US. This was launched mid-quarter, and it's an important initiative for our veterinary services business to continue to strengthen our position in America and also tap into a market that we were unable to reach in the past.
Our margins improved from 25.4% to 30.3%, and again, it was driven by the growth.
Also, we have a positive geographic mix for our vet services business.
Now turning to diagnostics.
Um, again, uh, for the second consecutive quarter, we delivered double-digit growth here at 16%, driven by our livestock segment. And, um, also, as we have told everybody before, we are continuing to invest in rolling out a product in the companion animal space, which is why our earnings continue to be at the level that they are. So we're making investments in further market growth.
And before I let you go through the financials, I want to spend a little bit of time discussing our progress on ESG. First of all, during the quarter, we improved our ESG rating with MSCI from an A to a double A.
So we're pleased about the progress that we're making there.
Now when we look back and reflect on 2024, we've reduced our emissions and we've strengthened our supplier controls. Both of those are very important focused initiatives that we've been running. We're continuing to work on creating a great place to work at. And we trained all of our employees in business ethics, which is highly important to us. We also educated more than 40,000 veterinary professionals throughout the year, and that is also one of our key metrics and key methods in which we can unlock market growth. We continue to be committed to the ESG strategy and drive positive change in the world.
And with that said, I'm going to hand over to Karl-Johan to walk us through some of the details in the financials.